Effect of etanercept in polymyalgia rheumatica: A randomized controlled trial

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Kreiner, Frederik ^a   Galbo, Henrik ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; GLUCOCORTICOID; INTERLEUKIN 6; PLACEBO; TRAMADOL; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INJECTION SITE RASH; MALE; MOBILIZATION; MONOTHERAPY; MORNING STIFFNESS; PAIN ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC POLYMYALGIA; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYMYALGIA RHEUMATICA; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956634308     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3140     Document Type: Article

References (32)

1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008, 372:234-245. 10.1016/S0140-6736(08)61077-6, 18640460.
2. Salvarani C, Barozzi L, Cantini F, Niccoli L, Boiardi L, Valentino M, Pipitone N, Bajocchi G, Macchioni P, Catanoso MG, Olivieri I, Hunder GG. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008, 67:758-761. 10.1136/ard.2007.084723, 18208867.
3. Healey LA. Polymyalgia rheumatica is the result of synovitis. J Clin Rheumatol 2006, 12:165-166. 10.1097/01.rhu.0000230445.14861.fa, 16891917.
4. Cantini F, Niccoli L, Nannini C, Padula A, Olivieri I, Boiardi L, Salvarani C. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005, 23:462-468.
5. Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008, 44:207-220. 10.1016/j.cyto.2008.09.004, 18986814.
6. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A, Fernandez-Sola J, Urbano-Marquez A, Grau JM, Cid MC. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002, 47:29-35. 10.1002/art1.10161, 11932875.
7. Uceyler N, Schafers M, Sommer C. Mode of action of cytokines on nociceptive neurons. Exp Brain Res 2009, 196:67-78. 10.1007/s00221-009-1755-z, 19290516.
8. Uceyler N, Sommer C. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett 2008, 437:194-198. 10.1016/j.neulet.2008.03.050, 18403115.
9. Kreiner F, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum 2010,
10. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002, 347:261-271. 10.1056/NEJMra011913, 12140303.
11. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997, 40:1873-1878. 10.1002/art.1780401022, 9336424.
12. Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P, Fazzuoli L, Villaggio B, Seriolo B, Sulli A. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006, 65:1438-1443. 10.1136/ard.2006.051979, 1798362, 16644782.
13. Nothnagl T, Leeb BF. Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica. Drugs Aging 2006, 23:391-402. 10.2165/00002512-200623050-00003, 16823992.
14. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009, 5:531-541. 10.1038/nrrheum.2009.182, 19798027.
15. Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, Cimmino M, Gerli R, Catanoso MG, Boiardi L, Cantini F, Klersy C, Hunder GG. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007, 146:631-639.
16. Keystone EC. Switching tumor necrosis factor inhibitors: an opinion. Nat Clin Pract Rheumatol 2006, 2:576-577. 10.1038/ncprheum0339, 17075592.
17. Migliore A, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F, Dibiase N, Alimonti A, Granata M. TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report. Eur Rev Med Pharmacol Sci 2005, 9:373-378.
18. Corrao S, Pistone G, Scaglione R, Colomba D, Calvo L, Licata G. Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study. Clin Rheumatol 2009, 28:89-92. 10.1007/s10067-008-1026-6, 18946712.
19. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, Lopez-Longo J, Figueroa M, Belzunegui J, Mola EM, Bonilla G. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630. 10.1136/ard.2007.082115, 18086726.
20. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259. 10.1056/NEJM199901283400401, 9920948.
21. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982, 97:672-680.
22. Randomization.com. , http://randomization.com
23. Thorsen H, Hansen TM, McKenna SP, Sorensen SF, Whalley D. Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J Rheumatol 2001, 30:103-109. 10.1080/03009740151095402, 11324786.
24. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004, 63:1279-1283. 10.1136/ard.2003.011379, 1754762, 15361387.
25. Binard A, de Bandt M, Berthelot JM, Saraux A. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 2008, 59:263-269. 10.1002/art.23338, 18240260.
26. Binard A, Lefebvre B, De Bandt M, Berthelot JM, Saraux A. Validity of the polymyalgia rheumatica activity score in primary care practice. Ann Rheum Dis 2009, 68:541-545. 10.1136/ard.2008.088526, 18477738.
27. Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ, Powell RJ, Todd I. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 2006, 45:31-37. 10.1093/rheumatology/kei090, 16287931.
28. Andonopoulos AP, Meimaris N, Daoussis D, Bounas A, Giannopoulos G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003, 62:1116. 10.1136/ard.62.11.1116, 1754369, 14583578.
29. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
30. Hernandez-Rodriguez J, Segarra M, Vilardell C, Sanchez M, Garcia-Martinez A, Esteban MJ, Queralt C, Grau JM, Urbano-Marquez A, Palacin A, Colomer D, Cid MC. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004, 43:294-301. 10.1093/rheumatology/keh058, 14679293.
31. Salvarani C, Pipitone N, Boiardi L, Hunder GG. Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?. Ann Rheum Dis 2008, 67:577-579. 10.1136/ard.2007.086330, 18408108.
32. Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L, Padula A, Olivieri I, Boiardi L. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003, 30:760-763.